Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase
Kynurenine-3-monooxygenase (KMO) is an emerging clinical target for treatment of neurodegenerative diseases and acute pancreatitis. Here, the authors report potent inhibitors that bind KMO in an unexpected conformation, offering structural and mechanistic insights for future drug discovery ventures.
Enregistré dans:
Auteurs principaux: | Jonathan P. Hutchinson, Paul Rowland, Mark R. D. Taylor, Erica M. Christodoulou, Carl Haslam, Clare I. Hobbs, Duncan S. Holmes, Paul Homes, John Liddle, Damian J. Mole, Iain Uings, Ann L. Walker, Scott P. Webster, Christopher G. Mowat, Chun-wa Chung |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2017
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/6a2d1e05cbf54050aa6e26f4834e4b9a |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Full-length in meso structure and mechanism of rat kynurenine 3-monooxygenase inhibition
par: Shinya Mimasu, et autres
Publié: (2021) -
Ablation of kynurenine 3-monooxygenase rescues plasma inflammatory cytokine levels in the R6/2 mouse model of Huntington’s disease
par: Marie Katrin Bondulich, et autres
Publié: (2021) -
Kynurenine and depressive symptoms in a poststroke population
par: Bensimon K, et autres
Publié: (2014) -
An ancient family of lytic polysaccharide monooxygenases with roles in arthropod development and biomass digestion
par: Federico Sabbadin, et autres
Publié: (2018) -
Structural and electronic determinants of lytic polysaccharide monooxygenase reactivity on polysaccharide substrates
par: T. J. Simmons, et autres
Publié: (2017)